Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Barry D. Hock"'
Autor:
Barry D Hock, Liping Goddard, Sean A MacPherson, Matthew Strother, David Gibbs, John F Pearson, Judith L McKenzie
Publikováno v:
PLoS ONE, Vol 18, Iss 9, p e0290793 (2023)
The efficacy of PD-1 monoclonals such as pembrolizumab can be modulated by the signals delivered via their Fc region. Tumour/inflammation associated proteases can generate F(ab')2 fragments of therapeutic monoclonals, and subsequent recognition of F(
Externí odkaz:
https://doaj.org/article/5c5343f1c5614282a9d7c4d55c3316c4
Publikováno v:
Free Radical Research. 56:366-377
CD36 is the key scavenger receptor driving the formation of cholesterol-loaded foam cells, the principal cellular component of atherosclerotic plaques. CD36 is down regulated by 7,8-dihydroneopterin, a potent superoxide and hypochlorite scavenging an
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0172858 (2017)
Chronic lymphocytic leukemia (CLL) is associated with T cell dysfunction. Activated CLL cells are found within the lymphoid tumor micro-environment and overcoming immuno-suppression induced by these cells may improve anti-CLL immune responses. Howeve
Externí odkaz:
https://doaj.org/article/648b66cda15e476387039ffffba17694
Autor:
Linda A. Buss, Abel Damien Ang, Bridget A. Robinson, Barry D. Hock, Gabi U. Dachs, Margaret J. Currie, Liping Goddard
Publikováno v:
Immunology Letters. 234:13-15
Autor:
Barry D. Hock, Linda A. Buss, Abel Damien Ang, Bridget A. Robinson, Margaret J. Currie, Troy L. Merry, Gabi U. Dachs
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 10, p e0258831 (2021)
PLoS ONE, Vol 16, Iss 10, p e0258831 (2021)
Cancer causes mitochondrial alterations in skeletal muscle, which may progress to muscle wasting and, ultimately, to cancer cachexia. Understanding how exercise adaptations are altered by cancer and cancer treatment is important for the effective des
Autor:
Linda A. Buss, Gabi U. Dachs, Bridget A. Robinson, Abel Damien Ang, Margaret J. Currie, Barry D. Hock, Thomas Williams
Publikováno v:
Immunology letters. 239
Immune checkpoint inhibition is highly effective in treating a subset of patients with certain cancers, such as malignant melanoma. However, a large proportion of patients will experience treatment resistance, and other tumour types, such as breast c
Autor:
John F. Pearson, Peter Ganly, Katie S. Mulholland, Judith L. McKenzie, Sean A. MacPherson, Barry D. Hock
Publikováno v:
Internal Medicine Journal. 49:598-606
BACKGROUND The impact of changes in novel agent (NA) usage on the survival of multiple myeloma (MM) patients in real-world hospital settings is unclear. In New Zealand (NZ) in 2011, frontline bortezomib became available and thalidomide availability w
Autor:
Barry D. Hock, Shwan Karim, Michael Schultz, Lisa K. Stamp, Esther T. Johanna Helms, Paula E. Keating, Murray L. Barclay
Publikováno v:
Internal Medicine Journal. 49:513-518
BACKGROUND Therapeutic drug monitoring of anti-tumour necrosis factor (TNF) drugs and anti-drug antibodies (ADA) is now recommended in the treatment of inflammatory bowel disease. However, assay types and drug concentration thresholds are still debat
Autor:
Stewart M. Smith, Barry D. Hock, Christopher J McEntyre, Judith L. McKenzie, Paula E. Keating, Liping Goddard
Publikováno v:
Therapeutic Drug Monitoring. 40:705-715
The measurement of anti-drug antibody (ADA) levels in adalimumab (ADAL)-treated and infliximab (IFX)-treated patients is critical for guiding therapeutic strategies. The homogeneous mobility shift assay (HMSA) and affinity capture elution (ACE) assay
Autor:
Gabi U. Dachs, Linda A. Buss, Margaret J. Currie, Bridget A. Robinson, Abel Damien Ang, Barry D. Hock
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 3, p e0229290 (2020)
PLoS ONE, Vol 15, Iss 3, p e0229290 (2020)
Preclinical studies have shown a larger inhibition of tumour growth when exercise begins prior to tumour implant (preventative setting) than when training begins after tumour implant (therapeutic setting). However, post-implantation exercise may alte